Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Female Health initiates Stage 1 of a bioequivalence clinical trial designed to select the optimal formulation of its proprietary Tamsulosin Delayed Release Sachet product (1.05)Assuming successful Stage 1 data, Stage 2 of the clinical trial will test the selected formulation from Stage 1 in a larger number of subjects versus FLOMAX. The goal is to have Stage 2 of the clinical trial completed by late May 2017. Stability data is also being collected for the commercial manufactured drug batches to allow an anticipated NDA filing late 2017 / early 2018. The expected NDA approval would be sometime in mid to late 2018.</td> </tr></table>"